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http:WHAT THIS PAPER ADDS
This work demonstrates that in addition to the neutralizing effects of plasma proteins on sclerosant activity,
circulating blood cells also consume and deactivate detergent sclerosants. This study reinforces our previous
clinical recommendations that discourage extensive mixing of detergent sclerosants with intravascular blood.Objective: To investigate the deactivating effects of circulating blood cells on the lytic activity of detergent
sclerosants.
Methods: Samples of whole blood (WB), platelet-rich plasma (PRP), and isolated leukocytes were incubated with
various concentrations of sodium tetradecyl sulfate (STS) or polidocanol (POL) and added to human umbilical
vein endothelial cells (HUVECs), which were then counted using a ﬂuorescent plate reader. Full blood counting
was performed using a hematology analyzer. Platelet lysis and microparticle formation was assessed using
lactadherin binding in ﬂow cytometry.
Results: Detergent sclerosant activity was decreased in WB when compared with plasma and saline controls. The
sclerosant lytic activity on endothelial cells was increased 23-fold for STS and 59-fold for POL in saline controls
compared with WB. At high concentrations, sclerosants lysed erythrocytes, leukocytes, and platelets. Platelets
were more sensitive to the lytic activity of sclerosants than other cell types. Neutrophils were the most
susceptible of all leukocytes to the lytic activity of sclerosants. The presence of erythrocytes and leukocytes in
samples decreased the lytic activity of sclerosants. Sclerosants at all concentrations induced erythrocyte-derived
microparticle formation.
Conclusions: Detergent sclerosants are consumed and deactivated by circulating blood cells. This deactivating
effect is above and beyond the neutralizing effects of plasma proteins and contributes to the overall neutralizing
effect of blood. Different blood cell types exhibited varying levels of vulnerability to the lytic activity of
sclerosants with platelets being the most and erythrocytes the least vulnerable
(platelets > leukocytes > erythrocytes).
 2015 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Detergent sclerosants such as sodium tetradecyl sulfate
(STS) and polidocanol (POL) are injected in varicose veins or
vascular malformations with the intention of stimulating
endothelial lysis and vessel destruction. The intravascular
administration and in particular injection into large veins or
vascular lesions results in mixing of sclerosants with blood,
a reduction in the lytic activity and clinical potency.1responding author. K. Parsi, Dermatology, Phlebology and Fluid
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//dx.doi.org/10.1016/j.ejvs.2014.12.029Historically, the neutralizing effect of blood was attrib-
uted to dilution. This group successfully challenged this
notion and demonstrated that dilution only plays a small
part in the reduction of the lytic activity of sclerosants and
that binding to plasma proteins and in particular albumin
has a more signiﬁcant impact.2 Subsequently, we demon-
strated that both sclerosants, and in particular POL, are
signiﬁcantly more active when diluted in saline than in al-
bumin or in whole blood (WB). These ﬁndings were
conﬁrmed later by Watkins,3 who, using a titration based
method, demonstrated that approximately 0.5 mL of blood
is sufﬁcient to completely deactivate 1 mL of 3% STS. This
method was limited to STS and hence unable to detect the
active concentration of POL following mixing with blood.
Furthermore, as the main target of detergent sclerosants is
the endothelial layer of the target veins, a more appropriate
Sclerosant Deactivation by Blood Cells 427measure of sclerosant activity is the ability to induce
endothelial lysis. In the present study, it was postulated that
circulating blood cells deactivate sclerosants independent
of the role played by plasma proteins. The mechanism to
involve direct consumption of the active detergent in the
process of inducing the lysis of erythrocytes, leukocytes, and
platelets and the subsequent release of microparticles from
these cell types was hypothesized.
MATERIALS AND METHODS
Materials
STS was obtained as Fibrovein (3%) from Australian Medical
and Scientiﬁc Ltd. (Chatswood, NSW, Australia). POL was
obtained as Aethoxysklerol (3%) from Chemische Fabrik
Kreussler & Co (Wiesbaden, Germany). Flow cytometry
antibodies, Annexin V and TRUCount tubes were obtained
from Becton Dickinson (Franklin Lakes, NJ, USA). Bovine
serum albumin (BSA) was obtained from Sigma Aldrich (St.
Louis, MO, USA). Heparin was obtained from Pﬁzer, Phar-
macia and Upjohn (New York, NY, USA). Endothelial cell
growth supplement (ECGS) and bovine serum albumin (BSA)
were obtained from Sigma Aldrich. Calcein-AM, human
umbilical vein endothelial cells (HUVECs), Medium 199, and
all other cell culture reagents were obtained from Life
Technologies (Carlsbad, CA, USA) and grown on Corning
culture ware (Tewksbury, MA, USA).
Cell culture
HUVECs were cultured in media containing 20% fetal bovine
serum, 100 mg/mL heparin, 10 mM L-glutamine, 10 mL/mL
penicillin/streptomycin, 25 mL/mL HEPES, and 30 mg/mL
ECGS made up in Medium 199. Cells were grown in T75
culture ﬂasks.
Sample collection and preparation
Following informed consent, samples were collected from
normal healthy donors taking no medications or supple-
ments. WB was collected into 2.7-mL Vacutainer tubes
containing sodium citrate as the anticoagulant. Platelet-rich
plasma (PRP) was obtained after centrifugation of WB for
10 minutes at 150g. Platelet-poor plasma (PPP) was ob-
tained after centrifugation of WB for 20 minutes at 1,500g.
All experiments were performed with n  3, where n refers
to the number of repetitions of experiments using different
samples from the same donor.
HUVEC lysis assay
HUVECs (6  106 cells) were incubated with 1 mM calcein
for 15 minutes. Excess calcein was removed by centrifuga-
tion at 400g for 5 minutes replaced with 10 mL of PBS. A
50-mL sample of the cells was then transferred to 96-well,
black-wall plates that had been coated with poly-L-Lysine for
30 minutes. The cells were allowed to attach for 1 hour
before washing with PBS. In a separate 96-well plate,
varying concentrations (0e0.6%) of detergent sclerosants
were added to each blood sample type and 50 mL of thismixture was immediately transferred to the cultured
HUVECs. Samples were incubated for 15 minutes at 37 C,
following which cells were rinsed with PBS. The plate was
then reanalyzed using the ﬂuorescent plate reader and the
decrease in ﬂuorescence converted into a percentage lysis
value. A standard curve was generated for each milieu
(saline, plasma, and WB) containing serial dilutions of
endothelial cells in a ﬁxed volume of each milieu.
Sclerosant incubation
For all other remaining tests, all samples (WB, PRP, eryth-
rocyte suspensions, and platelet suspensions) were incu-
bated with varying concentrations of sclerosants (described
in Figs. 1e4) for 15 minutes at room temperature before
analysis.
Blood cell counting
Cell counting, including differential cell counting, was per-
formed using an automated hematology analyzer (Cell-Dyn,
Abbott Diagnostics, IL, USA) in 1 mL of WB samples diluted
with sclerosant.
Flow cytometric platelet and microparticle counting
Platelet and platelet microparticle (PMP) counting was
performed using ﬂow cytometry, as previously described.4
PMP counting was performed on an LSR-II ﬂow cytometer
(Becton Dickinson) using FACSDiva software.
Statistical analysis
Statistical analysis was performed using a paired t test using
Prism software (v6.03, GraphPad Software Inc., CA, USA).
RESULTS
Neutralization of sclerosant activity by blood components
The incubation of STS and POL with endothelial cells
resulted in lysis (Fig. 1), but this activity was inﬂuenced by
the diluent (saline, plasma, and WB). The concentration
required to achieve 50% endothelial lysis in saline was
extrapolated to be 0.09375%, and in WB was 0.22% (for
STS) and 0.55% (for POL). The sclerosant lytic activity on
endothelial cells was therefore increased 23-fold for STS
and 59-fold for POL in saline compared with WB.
We found both sclerosants achieved complete lysis of
target endothelial cells at 0.6% in WB. Preliminary experi-
ments were performed in concentrations up to 1.5% for
each sclerosant (results not shown). At these higher con-
centrations residual sclerosant molecules would be present
and available for lytic activity, despite the lack of any target
cells.
Lysis of whole blood components
Incubation of STS and POL with WB resulted in cell lysis
(Fig. 2). Incubation with the same concentration of scle-
rosants at 0.3% resulted in platelet lysis (100%), erythrocyte
lysis (25%), and leukocyte lysis (91% for STS, 32% for POL).
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Figure 1. The effect of detergent sclerosants on endothelial cell lysis. Human umbilical vein endothelial cells (A,B,C) and platelets (D,E,F)
were incubated in varying concentrations of sodium tetradecyl sulfate (STS, -) or polidocanol (POL, B) diluted using saline, plasma or
whole blood for 15 minutes (n ¼ 3). The concentration required to achieve 50% lysis was then quantiﬁed (dotted line). *p < .05 for STS
versus POL.
428 D.E. Connor et al.Lytic effect on leukocyte subtypes in whole blood
STS induced lysis of all leukocyte subtypes, whereas POL
signiﬁcantly decreased neutrophil counts, but not monocyte
or lymphocyte counts (Fig. 3). Neutrophils were the most
susceptible of all leukocytes to detergent-induced lysis.Effect of dilution medium on platelet lysis
Platelet lysis was then assessed using ﬂow cytometry for
platelets resuspended in saline, 5% BSA, plasma, or in their
native WB following incubation with STS and POL (Fig. 4).
These results should be interpreted bearing in mind that
PRP is saline containing additional protein and platelets and
that WB is plasma with the additional contribution of cells.0.0 0.1 0.2 0.3
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Figure 2. The effect of detergent sclerosants on cell counts. Whole blo
sodium tetradecyl sulfate (STS, -) and polidocanol (POL, B) for 15
erythrocyte, and (C) leukocyte counts.In summary, cells were the major contributor to the deac-
tivation of both agents: consistent with our previous ﬁnd-
ings. POL was more susceptible than STS to the deactivation
by blood.2Microparticle release
Incubation of WB with STS or POL stimulated PMP and red
blood cell microparticle (RMP) release (Fig. 4). Microparticle
counts progressively increased at lower concentrations of
sclerosants. Similar to our previous publications,2,5 at higher
concentrations (>0.3% for STS, >0.15% for POL) PMP
counts decreased, while there was no observed decrease in
RMP counts.0.0 0.1 0.2 0.3
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Figure 3. The effect of detergent sclerosants on differential blood counts. Whole blood samples (n ¼ 6) were incubated with varying
concentrations of (A) sodium tetradecyl sulfate (STS) and (B) polidocanol (POL) for 15 minutes before analysis for leukocyte differential
counting for neutrophils (-), lymphocytes (B), monocytes (▴), eosinophils (△) or basophils (♦).
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Detergent sclerosants are typically injected in blood vessels,
where they mix with the intravascular blood. Previous
studies by this group and others have demonstrated that
circulating plasma proteins such as albumin neutralize the
lytic activity of these agents.2,3,6 In this study, the lytic ac-
tivity of sclerosants on endothelial cells and circulating
blood cells (platelets, erythrocytes and leukocytes) was
investigated and it was demonstrated that in addition to
plasma proteins, circulating blood cells play a signiﬁcant
role in deactivation of detergent sclerosants.
It is well known that STS is more potent than POL in a
clinical setting.7 Similar to our previous ﬁndings,2 in this
study we observed that POL was more deactivated by blood
than STS. This difference was primarily due to deactivation
by blood components. This is highlighted in Fig. 1, where a
0.3% concentration of STS caused 70% lysis of endothelial
cells in WB, whereas the same concentration of POL only
caused 20% lysis. By contrast, both these agents achieved
the same degree of lysis in both saline and plasma. Clini-
cally, this means that POL would achieve the same lytic0
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Figure 4. Release of microparticles (MP) from erythrocytes and plate
concentrations of sodium tetradecyl sulfate (STS, -) or polidocanol (PO
platelet (PMP) or (B) red blood cell microparticles (RMP).activity as STS in a bloodless vein. Such conditions may be
achieved using foam sclerosants, perivascular tumescent
anesthesia, and irrigation of intravascular blood using sa-
line. These ﬁndings further explain why foam sclerosants are
clinically more potent that liquid agents in achieving better
treatment outcomes. Although the activity of foam scle-
rosants and the interaction with target cells is derived from
the liquid and not the gas component, foam sclerosants are
more potent than liquid agents. Foam sclerosants displace
blood better than liquid sclerosants (that allow more mix-
ing), therefore avoiding deactivation by circulating blood
cells.
In a previous study, Watkins3 used a titration-based assay
for investigating the active concentration of STS in solution
and determined that the neutralization of 1 mL of STS could
be achieved by the addition of 2.15 mL of “laboratory
blood”, comprising BSA and dried bovine erythrocytes. In
the present study, we extended this work by using human
plasma and blood cells. This model could be used to study
the activity of POL, which was not studied by Watkins et al.3
It was demonstrated that the sclerosant concentration0.45
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lets. Whole blood samples (n ¼ 3) were incubated with varying
L,B) for 15 minutes before ﬂow cytometry was performed for (A)
430 D.E. Connor et al.required to induce cell lysis was higher in blood than in
plasma. This ﬁnding highlights the signiﬁcance of circulating
blood cells in dampening the lytic activity of detergent
sclerosants. The mechanism most likely involves consump-
tion of the active surfactant by lipid structures including the
cytoplasmic membranes and phospholipid containing or-
ganelles such as the nuclear membrane and the endo-
plasmic reticulum.8
Detergent sclerosants are non-speciﬁc agents used in
membrane biochemistry to solubilize lipid membranes.8 In
this study, we have demonstrated that endothelial cells
have to compete with circulating blood cells for exposure to
active sclerosants. The incubation of detergent sclerosants
with WB resulted in lysis of circulating blood cells and hence
a decrease in the active sclerosant concentration available
to lyse the target endothelial cells (Figs. 1 and 2). In other
words, circulating blood cells consumed the detergent
sclerosants. The term “consumption” has been introduced
to describe the non-pharmacological mechanism of deacti-
vation of the sclerosant by circulating blood cells. This
should be differentiated from inhibition in a pharmacolog-
ical sense, which would involve mechanisms such as drug
methylation and sulfuration or inhibition of speciﬁc target
receptors or ligands.
It was demonstrated that different blood cells exhibit
varying levels of vulnerability to the lytic activity of scle-
rosants, with platelets being the most vulnerable followed
by leukocytes and erythrocytes. In addition, different
leukocyte subpopulations demonstrated different suscepti-
bilities with no detectable change in lymphocyte pop-
ulations when 0.3% POL was used. These ﬁndings are most
likely due to the variability in the composition of the cell
membranes (protein and phospholipid content) as well as
the cytoskeletal structure. Erythrocytes are anuclear,
therefore the phospholipid content is limited to the cell
membrane, whereas leukocytes contain other membranous
structures including the nucleus. Therefore, more detergent
would be required to completely lyse erythrocytes as
opposed to leukocytes and platelets in that order. It has
previously been shown that sclerosants activate platelets
and release PMPs9 and more recently it has been demon-
strated that sclerosants activate leukocytes and induce the
release of inﬂammatory and angiogenic cytokines at low
concentrations.10 One practical application of the current
results would be to determine appropriate concentrations
to induce cellular lysis while avoiding leukocyte and platelet
activation.
Another novel ﬁnding of this study was the release of
RMPs following incubation of WB with both sclerosants.
Similar to PMPs, RMPs also expressed the procoagulant
phosphatidylserine. Whereas PMPs would be expected to
be pro-inﬂammatory, it is likely that the activity of RMPs
would be limited to their procoagulant activity. At higher
sclerosant concentrations, PMP counts, but not RMP
counts, began to decrease. This is most likely reﬂective of
the complete lysis of platelets at these concentrations,
limiting the source of PMPs, but as demonstrated in Fig. 2
erythrocytes are still present as a cellular source of RMPs.This study further reinforces the previous clinical rec-
ommendations that discourage extensive mixing of deter-
gent sclerosants with intravascular blood. Mixing results in
consumption and deactivation of sclerosants, a decrease in
the ﬁnal active concentration, and a subsequent loss of
clinical efﬁcacy.2 In addition, a decrease in the concentra-
tion would result in procoagulant activity in the target
vessels and the adjoining deep veins.11 Direct injection into
large vascular spaces such as venous malformations should
be avoided as the large ratio of blood to sclerosant volume
would result in deactivation, a procoagulant proﬁle,
thrombus formation, and non-closure. Ancillary techniques
such as the preoperative administration of perivascular
tumescent anesthesia may be employed to reduce the
extent of mixing.
It may be argued that the use of foam sclerosants would
minimize the degree of mixing by displacing the intravas-
cular blood. In a recent study it was demonstrated that
three horizontal layers of foam (at the top), liquid scle-
rosant, and blood (at the bottom) are formed in the
vessel.12 This effect is more prominent at higher liquid-plus-
air fractions and at the foam front. This results in mixing of
the active liquid sclerosant with intravascular blood and
subsequent deactivation. Hence, although foam sclerosants
displace the intravascular blood and undergo less mixing
than liquid agents, there is substantial mixing at the foam
front.
This study had several limitations. The lytic activity of
the sclerosants and not the sclerosant concentration
following mixing with various media was investigated.
Further methods using titration-based assays3 need to be
developed to conﬁrm these ﬁndings. These experiments
were performed with incubation periods of 15 minutes.
Lower exposure times would possibly require higher
concentrations of sclerosants to achieve the same lytic
effect. This group has previously shown this effect in ex-
periments investigating the effect of sclerosants on
platelets.5
These in vitro experiments were conducted under static
hemodynamic conditions, where the sclerosant is exposed
to target cells for a ﬁxed period of time. In vivo, ﬂow con-
ditions would inﬂuence the exposure of target cells to the
active sclerosing agents. In low ﬂow conditions, such as in
veins and venous malformations, sclerosants enjoy pro-
longed exposure to their target endothelial cells, which may
explain the relative success of these agents in treating these
conditions. The long incubation time used in this study was
consistent with the prolonged endothelial exposure in low
ﬂow conditions. However in a high ﬂow hemodynamic
state, the sclerosant would be washed away, reducing the
exposure of the endothelial lining of the target lesion to the
active agents. Furthermore, the high ﬂow conditions would
result in more mixing with intravascular blood and hence
more deactivation of the sclerosant. This group is currently
investigating the activity of sclerosants in high ﬂow lesions
such as arteriovenous malformations.
In summary, detergent sclerosants induced lysis of
circulating blood cells and released procoagulant
Sclerosant Deactivation by Blood Cells 431microparticles from erythrocytes and platelets. Different
cell types demonstrated varying sensitivities to sclerosant-
induced lysis. Deactivation of sclerosants by blood was
not exclusive to plasma proteins and circulating blood cells
played a crucial role in the deactivation process.
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